✦ LIBER ✦

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

✍ Scribed by N. L. Steele; J. A. Plumb; L. Vidal; J. Tjørnelund; P. Knoblauch; P. Buhl-Jensen; R. Molife; R. Brown; J. S. de Bono; T. R. J. Evans

Publisher: Springer
Year: 2010
Tongue: English
Weight: 298 KB
Volume: 67
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-010-1419-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Plasma and cerebrospinal fluid pharmacok

Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates

✍ Katherine E. Warren; Cindy McCully; Henrik Dvinge; Jette Tjørnelund; Maxwell Seh 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 237 KB

Activity of the histone deacetylase inhi

Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer

✍ Xiaozhong Qian; Gulshan Ara; Evan Mills; William J. LaRochelle; Henri S. Lichens 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 751 KB

## Abstract Histone deacetylase inhibitors (HDACi) represent a promising new class of anticancer agents. In the current investigation, we examined the activity of the HDACi belinostat in preclinical models of prostate cancer. __In vitro__ proliferation assays demonstrated that belinostat potently i

Phase II study of the histone deacetylas

Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)

✍ Amanda Cashen; Mark Juckett; Alcee Jumonville; Mark Litzow; P. J. Flynn; John Ec 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 131 KB

The histone deacetylase inhibitor PXD101

The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models

✍ Young-Soon Na; Kyung-Ah Jung; Seung-Mi Kim; Yong Sang Hong; Min-Hee Ryu; Se Jin 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 874 KB